COGT News and Press, Cogent Biosciences Inc Com From 11/17/23

2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy  ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...

Cogent Biosciences Inc. (COGT) is expected to report $-0.5 for Q3 2023

2023-11-02 10:38:04 ET More on Cogent Biosciences Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor Seeking Alpha’s Quant Rating on Cogent Biosciences For further details see: Cogent Biosciences GAAP EPS of -$0.64

SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSM data selected for oral presentation SUMMIT Part I completed upsized enrollment during Q3; SUMMIT Part 2 expected to begin in 1H 2024 at over 50 sites globally 33% ORR and >14 ...

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and initiation of clinical trial planned in 2H 2024 - WALTHAM, Mass. and BOULDER, Colo...

2023-08-15 17:03:09 ET Summary Cogent Biosciences, Inc. is developing the lead asset bezuclastinib, a KIT inhibitor, in various indications. The company has demonstrated positive clinical data for bezuclastinib in advanced systemic mastocytosis. Cogent Bio's financials show a ...

2023-08-08 09:58:24 ET Cogent Biosciences press release ( NASDAQ: COGT ): Q2 GAAP EPS of -$0.59. As of June 30, 2023, cash, cash equivalents and marketable securities were $350.9 million, as compared to $220.3 million as of March 31, 2023. For further details se...

Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023 Enrollment for Phase 3 PEAK trial in GIST continues on track Selective FGFR2 inhibitor nominated as first Cogent-discovered clinical candi...

WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public off...

WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Jefferies Healthcare Co...